WBB Securities Maintains Strong Buy on Cidara Therapeutics, Adjusts Price Target To $40 (reverse stock split - 1:20)
Portfolio Pulse from Benzinga Newsdesk
WBB Securities analyst Stephen Brozak has maintained a Strong Buy rating on Cidara Therapeutics (NASDAQ:CDTX) and adjusted the price target to $40, taking into account a 1:20 reverse stock split.
April 25, 2024 | 7:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
WBB Securities maintains a Strong Buy rating on Cidara Therapeutics, adjusting the price target to $40 post a 1:20 reverse stock split.
The maintenance of a Strong Buy rating by a reputable analyst, along with an adjusted price target that reflects a reverse stock split, is likely to be viewed positively by the market. This endorsement could lead to increased investor confidence in CDTX, potentially driving up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100